Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

C&C Vision CrystaLens “Accommodating” IOL Endorsed By FDA Panel

This article was originally published in The Gray Sheet

Executive Summary

C&C Vision's Model AT-45 CrystaLens likely will be the first intraocular lens (IOL) to reach the U.S. market with lens accommodation as its mechanism of action
Advertisement

Related Content

CrystaLens Accommodating IOL First To Market; Firm Eyes Expanded Labeling
CrystaLens Accommodating IOL First To Market; Firm Eyes Expanded Labeling
Staar’s ICL Panel Review In Sight; Three-Year Data Will Support PMA
Staar’s ICL Panel Review In Sight; Three-Year Data Will Support PMA
Advertisement
UsernamePublicRestriction

Register

MT018420

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel